p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines
Authors
Keywords
-
Journal
Cancer Research and Treatment
Volume 47, Issue 3, Pages 501-508
Publisher
Korean Cancer Association
Online
2014-11-24
DOI
10.4143/crt.2014.054
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients
- (2014) Hee Kyung Ahn et al. Translational Oncology
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
- (2013) William Greenhalf et al. JNCI-Journal of the National Cancer Institute
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- p21-activated kinases and gastrointestinal cancer
- (2012) Hong He et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- p21-Activated kinase inhibitors: a patent review
- (2012) James J Crawford et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
- (2012) Raphaël Maréchal et al. GASTROENTEROLOGY
- MUC13 Mucin Augments Pancreatic Tumorigenesis
- (2011) S. C. Chauhan et al. MOLECULAR CANCER THERAPEUTICS
- Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
- (2011) C. C. Ong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel tumor suppressive function of Smad4 in serum starvation-induced cell death through PAK1–PUMA pathway
- (2011) S-H Lee et al. Cell Death & Disease
- p21-Activated Kinase-1 Promotes Aggressive Phenotype, Cell Proliferation, and Invasion in Gestational Trophoblastic Disease
- (2010) Michelle K.Y. Siu et al. AMERICAN JOURNAL OF PATHOLOGY
- Copy number alterations in pancreatic cancer identify recurrentPAK4amplification
- (2010) Shuaili Chen et al. CANCER BIOLOGY & THERAPY
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
- (2010) Giuseppe Colucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Phenotype and Genotype of Pancreatic Cancer Cell Lines
- (2010) Emily L. Deer et al. PANCREAS
- Pak protein kinases and their role in cancer
- (2009) Bettina Dummler et al. CANCER AND METASTASIS REVIEWS
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- PAK signaling in oncogenesis
- (2009) P R Molli et al. ONCOGENE
- A tale of two Paks
- (2008) Luis E. Arias-Romero et al. BIOLOGY OF THE CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search